Meeting NewsVideo

VIDEO: SGLT-2 inhibitors provide positive cardiorenal outcomes

PHILADELPHIA — In this video exclusive, Mark E. Cooper, AO, PhD, head of the department of diabetes at Monash University in Melbourne, Australia, outlines some of the highlights of his presentation at Heart in Diabetes, which focused on how the kidney and heart interact to affect cardiovascular health for patients with diabetes.

Cooper discusses tools that can be used to treat patients with both kidney disease and CVD who also have diabetes, including SGLT-2 inhibitors, which may lead to superior glycemic management and reduced instances of failure of the kidneys and the heart.

Watch the video for more.

PHILADELPHIA — In this video exclusive, Mark E. Cooper, AO, PhD, head of the department of diabetes at Monash University in Melbourne, Australia, outlines some of the highlights of his presentation at Heart in Diabetes, which focused on how the kidney and heart interact to affect cardiovascular health for patients with diabetes.

Cooper discusses tools that can be used to treat patients with both kidney disease and CVD who also have diabetes, including SGLT-2 inhibitors, which may lead to superior glycemic management and reduced instances of failure of the kidneys and the heart.

Watch the video for more.

    See more from Heart in Diabetes